https://kstockbriefing.com
![[Disclosure] Samsung Biologics (207940) – Results of Extraordinary General Meeting of Shareholders / 2025-10-17](https://kstockbriefing.com/wp-content/uploads/2026/07/포맷변환-삼성바이오로직스.jpg)
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has disclosed that Agenda Item No. 1, ‘Approval of Spin-off Plan’, was approved as originally proposed at the 15th Extraordinary General Meeting of Shareholders held on October 17, 2025. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verifying…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has issued an advance notice disclosing that it plans to announce its Q3 2025 financial results (covering Jan 1, 2025 – Sep 30, 2025) on October 28, 2025. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verifying Official…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has obtained final marketing approval from the US Food and Drug Administration (FDA) for ‘Eydenzelt’ (CT-P42, ingredient: aflibercept), a biosimilar to Eylea, covering all primary indications including wet age-related macular degeneration. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌…
![[Disclosure] ALTEOGEN (196170) – Investor Relations (IR) Host / 2025-10-10](https://kstockbriefing.com/wp-content/uploads/2026/08/포맷변환알테오젠.jpg)
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary ALTEOGEN will host an overseas Non-Deal Roadshow (NDR) in Hong Kong, sponsored by CLSA, targeting major foreign institutional investors to present its platform technologies and pipeline status/plans. 📊 [Key Disclosure Details & Major Figures Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Platform Technologies…
Read More “[Disclosure] ALTEOGEN (196170) – Investor Relations (IR) Host / 2025-10-10” »
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary ALTEOGEN announced that it is scheduled to receive a milestone payment of USD 25M (approx. KRW 35.06B) following US FDA marketing approval for the subcutaneous (SC) formulation of Pembrolizumab using ALT-B4 licensed to MSD. 📊 [Key Disclosure Details & Major Figures Summary] 📝 Editor’s Comment (Key…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has issued an investor caution notice disclosing that, due to its corporate spin-off decision, the final trading day for stock futures and options (Nov ’25 through Sep ’26 contracts) will be changed to October 29, 2025, and new contract months will not be listed…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has disclosed a board resolution to convene the 15th Extraordinary General Meeting of Shareholders on October 17, 2025, at Songdo Convensia to vote on the approval of the spin-off plan. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary ALTEOGEN will issue and list 40,820 additional common shares following the exercise of stock options by executives and employees. The listing date is set for September 30, 2025. 📊 [Key Disclosure Details & Major Figures Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Additional…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Following the expiration of confidentiality deferrals, Celltrion disclosed that its 100% US subsidiary, Celltrion USA, Inc., has signed a definitive agreement to acquire Imclone Systems LLC from an Eli Lilly subsidiary for approx. KRW 460.0B (USD 330M). 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion’s 100% US subsidiary, Celltrion USA, Inc., has decided to acquire a 100% equity stake in Imclone Systems LLC from Eli Lilly Group for approx. KRW 460.0B (USD 330M) to establish a local US API manufacturing base. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s…